Implementation of Dialyzable Leukocyte Extract to Treat Multiple Sclerosis: A Clinical Case

Abstract

Multiple sclerosis (MS) is an autoimmune demyelinating disease that affects the central nervous system (CNS) with its chronic inflammatory component. In the treatment of MS, corticosteroids are usually implemented to reduce the disease's inflammation rate. In this case study, we present a patient with MS that initially received corticosteroids, which heightened his vulnerability to infections, particularly respiratory ones. Consequently, the treatment was changed to the administration of dialyzable leukocyte extract (DLE) ``Oral Transferon{''}. To this day, the rate of inflammation has been reduced, slowing the evolution of MS, decreasing the clinical manifestations of the disease, and improving the patient's quality of life. This may be attributed to the immunomodulatory effects of the Transferon. More studies are needed in MS patients implementing a treatment based solely on Transferon to establish its effectiveness as an immunomodulator (specifically for this autoimmune disease).